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Abstract
HIV-infected individuals with latent Mycobacterium tuberculosis (Mtb) infection are at significantly greater risk of reactivation
tuberculosis (TB) than HIV-negative individuals with latent TB, even while CD4 T cell numbers are well preserved. Factors
underlying high rates of reactivation are poorly understood and investigative tools are limited. We used cynomolgus
macaques with latent TB co-infected with SIVmac251 to develop the first animal model of reactivated TB in HIV-infected
humans to better explore these factors. All latent animals developed reactivated TB following SIV infection, with a variable
time to reactivation (up to 11 months post-SIV). Reactivation was independent of virus load but correlated with depletion of
peripheral T cells during acute SIV infection. Animals experiencing reactivation early after SIV infection (,17 weeks) had
fewer CD4 T cells in the periphery and airways than animals reactivating in later phases of SIV infection. Co-infected animals
had fewer T cells in involved lungs than SIV-negative animals with active TB despite similar T cell numbers in draining lymph
nodes. Granulomas from these animals demonstrated histopathologic characteristics consistent with a chronically active
disease process. These results suggest initial T cell depletion may strongly influence outcomes of HIV-Mtb co-infection.
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Introduction
Approximately 90% of human Mycobacterium tuberculosis (Mtb)
infections are clinically latent and likely represent an immune
response that successfully limits bacterial growth, resulting in
persistence within multi-cellular structures called granulomas [1].
While granulomas are composed of many different cell types,
macrophages and T cells are important components that
collaborate to limit bacterial replication and prevent dissemina-
tion. The immune response of immunocompetent individuals can
prevent active tuberculosis for years or decades, and latently
infected individuals have only a 5–10% lifetime risk of developing
reactivated tuberculosis (TB) [2]. Immunosuppressed individuals
have a significantly greater chance of developing active disease,
and TB is the leading killer of individuals infected with human
immunodeficiency virus (HIV) [3]. In contrast to most opportu-
nistic infections, which present in the later stages of HIV infection,
TB afflicts HIV-positive individuals throughout the course of
infection, even while CD4 numbers are well preserved [4,5,6].
While factors explaining the high rates of reactivated TB in co-
infected humans remain unclear, depletion of CD4 T cells [7] and
increased virus loads [8] within granulomatous tissue may be
contributors.
Co-infections in humans, and the accompanying immune
responses, are inherently difficult to investigate and studies are
frequently confounded by uncontrolled variables. Our current
understanding of immune responses to HIV-Mtb co-infection
comes predominantly from human clinical studies [8,9]. As with
all clinical studies involving human subjects, there are limitations
to studies that can be performed with HIV-Mtb co-infected
individuals. Some challenges include difficulty determining which
infection occurred first and when, limited availability of pre- and
post-infection samples, restrictions on unnecessary invasive
procedures to obtain tissue samples, and limited availability of
post mortem tissue samples for immunologic analysis. Addition-
ally, most HIV-TB clinical studies are in individuals with active
tuberculosis, and cannot fully explore the events that precede or
occur during reactivation. Human studies also have numerous
uncontrolled variables including the undefined status of the
immune system prior to infection and the presence of other
undiagnosed co-infecting pathogens that may have an effect on the
host immune response. Consequently, a biologically relevant
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animal model of HIV-Mtb co-infection where the amount and
sites of sampling could be increased and the confounding variables
minimized would be an extremely valuable asset.
Good animal models for HIV and TB exist, but there is not a
model which recapitulates HIV-infection in an individual with
latent TB. Macaques are frequently used to model HIV by
infection with simian immunodeficiency virus (SIV) or SHIV, a
HIV-SIV chimera. Depending on the macaque species and the
virus type used, these animals can be excellent models for human
infection and disease [10,11,12,13,14,15,16,17]. Macaques are
also valuable in studying tuberculosis [18,19,20,21,22,23]. Cyno-
molgus macaques infected with a low number of Mtb bacilli
develop clinical signs and pathology similar to humans with active
TB or develop subclinical latent infections, with equal proportions
of each infection outcome observed [18,21]. Moreover, latency
can be maintained for significant time periods. In our experience
working with cynomolgus macaques over the past decade, only
two of approximately 85 latently infected monkeys spontaneously
reactivated [13,19, unpublished data]. Thus, cynomolgus ma-
caques with latent TB have a ,5% chance of spontaneously
reactivating TB within a few years of infection and can maintain
this latent state for years [18,24].
Nonhuman primates have been used to examine interactions
between SIV and mycobacteria. Macaques co-infected with SIV
and Mtb (strain H37Rv) [25] or SIV and M. bovis BCG [20,26]
have been used to examine how mycobacteria induce AIDS-like
symptoms. Rhesus (M. mulatta) or pigtail (M. nemestrina) macaques
were inoculated with mycobacteria after SIV infection or
simultaneously co-infected with BCG and SIV [20,26]. These
studies indicated that SIV could be immunosuppressive and
sometimes exacerbate mycobacterial disease. Despite the range of
model systems available, similar studies into disease processes
underlying reactivated TB in HIV-infected humans with latent TB
have yet to be done.
In the current study we use cynomolgus macaques infected
with SIVmac251, a virulent HIV-like virus, to develop a novel
model of HIV-induced reactivated TB. We used this model to
examine immunologic, microbiologic and virologic changes in
the peripheral blood and tissues that have not been extensively
investigated in human or nonhuman primate HIV/SIV-Mtb co-
infection studies. Co-infected animals showed a spectrum of
disease severity, with the animals that reactivated ,17 weeks
post-SIV infection experiencing more severe pathology than
animals that reactivated .26 weeks post-SIV infection. We found
that time to reactivation correlated with significant peripheral
CD4 T cell depletion but not virus load during the acute phase of
SIV infection. The co-infected animals had fewer T cells in lung
tissue than SIV-negative macaques with active TB, and a trend
towards fewer T cells in the pulmonary lymph nodes than SIV-
only macaques. We also present evidence of rapid impaired local
control of latent Mtb infection, following SIV infection. These
studies pave the way for detailed investigations of factors
underlying reactivated TB in HIV-Mtb co-infected humans that
were not previously possible.
Materials and Methods
Ethics Statement
All experimental manipulations and protocols were approved by
the University of Pittsburgh School of Medicine Institutional
Animal Care and Use Committee. The animals were housed and
maintained in accordance with standards established in the
Animal Welfare Act and the Guide for the Care and Use of
Laboratory Animals.
Experimental Animals
Fifteen adult (.4 years of age) cynomolgus macaques (Macaca
fascicularis) of Chinese origin were used for these studies (Covance,
Alice, TX; USA Valley Biosystems, West Sacramento, CA). Prior
to the study, animals were tested to ensure they were free of Mtb,
SIV, SHIV or simian retrovirus D infection. Animals were also
given physical and clinical examinations including differential
blood cell counts, erythrocyte sedimentation rate (ESR), serum
chemistry profile and thoracic radiography to ensure they were
free of underlying disease processes. All animals were given 14-day
prophylactic Bactrim (sulfamethoxazole and trimethoprim) treat-
ments to eliminate potential Pneumocystis colonization infection.
SIV-infected animals were housed under BSL-2 conditions while
Mtb-infected animals were housed under BSL-3 conditions.
Bronchoalveolar lavage (BAL), gastric aspirate and other proce-
dures were performed as previously described [18,21]. We used
historical controls from previous studies [18,21,unpublished data]
on animals with active and latent TB to minimize the number of
animals used in this study.
Mtb and SIV Infection
The experimental design of these studies is described in figure
S1. Ten animals were infected with ,25 CFU Erdman strain Mtb
via intra-bronchial instillation as previously described [21]. Mtb
infection was confirmed in all ten animals by conversion of
negative to positive tuberculin skin test and peripheral blood
mononuclear cells (PBMC) responses elevated from baseline in
lymphocyte proliferation (LPA) and PBMC enzyme-linked immu-
nosorbent spot (ELISPOT) assays. Animals were classified as latent
or active 8–10 months post infection with the criteria for latency
defined as TST positive but with no signs of clinical disease as
previously described [18,21]. Of the original ten animals infected
with Mtb, six were classified as latent and selected for SIV
infection. A seventh latent monkey (10405) and infected with the
same dose and strain of Mtb from another study, was added to this
group to increase the number of animals.
For SIV infection, concentrated SIVmac251 stock (kindly
provided by Dr. Keith Reimann, Beth Israel Deaconess Medical
Center, Harvard University) was diluted in RPMI medium, and
106–107 TCID50 units of virus injected intravenously. Seven
animals with latent TB and four Mtb-negative animals were
infected with SIV, with the four Mtb-negative animals designated
as the SIV-only control group. Historical data from latent and
active control monkeys were used for comparison to minimize the
number of animals needed for this study. Some data from these
monkeys, as well as full characterization of pathology and disease
outcome, has been published previously [18]. Criteria for assessing
reactivation included prolonged weight or appetite loss, elevated
erythrocyte sedimentation rate (ESR), Mtb-positive gastric aspirate
or BAL cultures, or radiographic evidence of lung involvement, as
shown in Table 1.
Necropsy Procedures
Animals were humanely euthanized and necropsied as previ-
ously described [21] when indicators of active TB were present (in
co-infected monkeys) or at the end of the study (11 months post-
SIV). Necropsies were conducted by veterinarians with substantial
experience examining Mtb-infected cynomolgus macaques (E.K.,
C.J.). Lung lobes, liver, spleen, and kidney were examined for
evidence of tuberculous disease. Similarly, thoracic, axillary and
inguinal lymph nodes were examined for the presence of
granulomas. All gross pathology associated with tuberculous
disease was recorded and quantified using a previously established
scoring system validated to differentiate latent from active
SIV and TB Co-Infection
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tuberculosis in this model [18]. Tissue (granulomas, lymph nodes,
uninvolved lung from each lobe, extrapulmonary organs) was
divided into pieces for histology and RNA isolation, and the
remainder was mechanically homogenized into single-cell suspen-
sion for immunologic and microbiologic analysis and virus load
determination. 30–40 samples per monkey were examined
histologically and used for bacterial, virologic and immunologic
assays. In several monkeys, gut tissue was obtained for analysis of
T cell frequencies. Bacterial numbers in tissues were quantified by
plating dilutions of tissue homogenate onto 7H10 agar plates and
the number of colony forming units (CFU) in the original sample
calculated after 4–6 weeks of incubation at 37uC/5% CO2.
Immunologic Analysis
Blood was drawn from SIV-only and co-infected animals every
week prior to and for the first eight weeks post infection.
Thereafter, blood was drawn from Mtb-SIV co-infected animals
every other week and SIV-only animals monthly. PBMC were
isolated via percoll gradient centrifugation as previously described
[27]. Axillary or inguinal lymph nodes were biopsied at pre-
infection, 4, 8 and 16 weeks post SIV infection. PBMC and lymph
node cells were subjected to flow cytometry and IFNc ELISPOT
assays. ELISPOT assays using tissue or BAL cells included
autologous monocyte-derived dendritic cells, as antigen-presenting
cells, as previously described [21,27].
ELISPOT Assays for Mtb- and SIV-Induced IFNc Responses
ELISPOT assays were performed as previously described
[21,27] with 150,000 PBMC or lymph node cells per well using
ELISPOT reagents with known cross reactivity against macaque
IFNc (MabTech, Mariemont, OH) [18]. Mtb antigens used in
ELISPOT were peptide pools (overlapping 20-mers; 10 ug/mL)
from CFP-10 (Rv3872) and ESAT-6 (Rv3875) synthesized by
Sigma-Genosys (Woodlands, TX). Peptide pools for viral antigens
gag, pol, env, tat, nef and rev (overlapping 20-mers) all used at
10 ug/mL, based on SIVmac239) were obtained from the AIDS
Research and Reference Reagent Program (National Institutes of
Health, Germantown, MD). Phorbol 12,13-dibutyrate (PDBu) and
ionomycin (50 nM and 10 uM final concentration respectively;
Sigma) were used as positive controls. Media-only wells were used
as negative controls. Cells in ELISPOT assays were incubated
with antigens for two days at 37uC/5% CO2 prior to being
developed as previously described [27] and read using an
ELISPOT plate reader (Cellular Technology LTD, Cleveland,
OH). All conditions were performed in duplicate wells. ELISPOT
data were normalized and expressed as SFU per 106 cells.
Flow Cytometry
All antibodies used for flow cytometry were direct conjugates
against human proteins and obtained from BD Biosciences (San
Jose, CA) unless otherwise noted. Approximately 16106 PBMC or
tissue cells were stained using combinations of the following
antibodies: CD3 (clone SP34-2), CD4 (clone L200), CD8 (clone
DK25 [Dako; Carpinteria, CA], clone SK-1, clone OKT8
[eBioscience; San Diego, CA]) CD29 (clone HUTS-29) and
CD69 (clone FN50) (clone 2H7 [eBioscience]). Cell phenotypes
were read with a LSR II flow cytometer (BD Biosciences) and
positively-stained populations gated using fluorochrome-matched
isotype antibodies as negative controls using the FlowJo software
package (Tree Star Inc., Ashland, OR).
Virus Load Determination
Quantitative real time reverse transcriptase (qRT-PCR) for the
SIV gag gene was used to measure virus loads as previously
described [27,28]. RNA was isolated from 16106 percoll gradient-
isolated PBMC or lymph node cells, and from 26105 BAL or
tissue cells using the Qiagen RNeasy kit (Valencia, CA). Plasma
virus load was determined by isolating RNA from 200 uL of
plasma using the Purelink Viral RNA/DNA mini kit (Invitrogen,
Carlsbad, CA) as per manufacturer’s instructions.
Statistical Analysis
Data were analyzed using Prism (Graphpad Software, San
Diego, CA). Pair-wise comparisons between groups (e.g. latent and
co-infected animals) was performed using the Mann-Whitney test
with p,0.05 considered statistically significant.
Results
CD4 T Cells Were Transiently Depleted in the Periphery of
SIV-Infected Animals Coincident with Peak Virus Load in
PBMC
We measured viral titers in SIV-infected animals to determine
how SIV infection correlated with reactivation or whether Mtb
infection influenced SIV loads. SIV titers in plasma, PBMC, and
lymph node cells were similar between co-infected monkeys and
SIV-only monkeys (Figure 1). Peak virus loads in PBMC and
plasma occurred at 2–3 weeks post SIV infection and then
declined to low levels for the duration of the study. The greatest
virus burden in BAL cells from co-infected monkeys occurred two
weeks after peak virus load in the peripheral blood. Virus loads in
cells from peripheral lymph nodes were not significantly different
between time points, but these sites maintained moderate virus
loads (104–106 copies/106 cells). We also compared peripheral
virus loads between co-infected and SIV-only monkeys to
determine whether Mtb infection modified peripheral virus loads
but did not find significant differences between these groups (data
not shown).
SIV Causes Reactivation of Latent Tuberculosis
We previously described the clinical, microbiologic, radiologic
and immunologic parameters used to define latent infection and
active disease in macaques and demonstrated that these are
validated by quantitative measurements of bacterial burden and
gross pathology at necropsy [18,21]. Briefly, latent monkeys are
asymptomatic and lack radiographic or microbiologic evidence of
Table 1. Clinical evidence for reactivated TB in co-infected
monkeys.
Monkey
Positive clinical indicator
of TB (week observed)a Necropsya
2407 GAb (4,9), increasing ESR (4,9,12), chest x-ray (9, 12) 12
1407 increasing ESRb (4,9,13), chest x-ray (14) 15
1207 GA (10), chest x-ray (6) 17
1807 BALb (16,17) 26
1907 BAL (17,34), GA (37,44), chest x-ray (37) 45
3007 increasing ESR (41,45), progressive
weight loss (37,41,45)
47
10405 chest x-ray (47) 48
aindicates weeks post-SIV infection.
bGA–gastric aspirate, ESR–erythrocyte sedimentation rate, BAL–bronchoalveolar
lavage.
doi:10.1371/journal.pone.0009611.t001
SIV and TB Co-Infection
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Mtb infection beyond three months post infection [18,21].
Reactivation is defined as evidence of active TB either by
microbiologic, radiographic or clinical parameters after a period
of stable latent infection [18]. Based on these criteria, three of the
seven co-infected monkeys with latent TB had findings consistent
with reactivated TB 12–17 weeks post-SIV infection while the
remaining four monkeys reactivated between 26–48 weeks post-
SIV (Table 1). Monkey 1807 was necropsied after positive BALs
and had relatively low necropsy and bacterial number scores,
suggesting that positive cultures from BALs do not necessarily
correlate with significant disease burden, but may signify the first
sign of reactivation [18]. Considering this, Monkey 1907 was
necropsied approximately 28 weeks after the first positive BAL and
with additional positive clinical results to confirm reactivation was
underway. While a spectrum of disease was observed, we loosely
categorized the monkeys according to time of reactivation: early
reactivation (reactivated TB in ,17 weeks post SIV infection) and
later reactivation (reactivated .26 weeks post SIV).
Relationship between Peripheral T Cell Depletion and
Virus Loads and Time to Reactivation
SIV infection affects lymphocyte numbers, and changes in CD4
and CD8 T cell numbers were followed in the PBMC and axillary
or inguinal lymph nodes (referred to here as peripheral lymph
nodes) of co-infected monkeys over the course of SIV infection to
better understand the dynamics between lymphocyte numbers and
reactivation. All monkeys experienced substantial declines in
numbers of CD4 and CD8 T cells in the PBMC (Figure 2) and
peripheral lymph nodes (Figure S2) between 2–4 weeks post SIV
infection, a time corresponding with peak viremia (Figure 2A).
After 8 weeks, T cells recovered to pre-SIV levels in all monkeys.
No differences in CD4 or CD8 frequencies were found between
Figure 1. SIV loads in plasma and PBMC ofMtb-SIV co-infected and SIV-onlymonkeys. No significant differences in plasma, peripheral blood
mononuclear cells (PBMC), bronchial alveolar lavage cells (BAL) or peripheral lymph node viral titer were observed between co-infected cynomolgus
macaques (red line, n = 7) or the SIV-only group (blue line, n = 4). We were unable to obtain enough BAL cells from SIV-only monkeys to reliably measure
virus load. The horizontal dashed line represents the detection limit for viral copy numbers. Lower error bars have been removed for clarity.
doi:10.1371/journal.pone.0009611.g001
SIV and TB Co-Infection
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SIV-only and co-infected animals (data not shown). Peripheral T
cell numbers in co-infected animals were averaged during acute
SIV infection (weeks 1–8 post-SIV) and plotted against the week
that either indicators of reactivated TB were noted or the week
that necropsy occurred to address the relationship between T cells
and reactivation. Necropsy time was based on the aggregate
clinical signs in a monkey. There was a significant correlation
between extent of depletion of CD4 T cell numbers 2–8 weeks
post-SIV and time to reactivation (P= 0.011, R2= 0.755) and
necropsy time (P= 0.0007, R2= 0.9172) (Figure 2B). The
correlation between reactivation signs and early depletion of
CD8 T cell was not significant (P = 0.112, R2= 0.425) but extent
of early depletion of CD8 T cells did correlate with time of
necropsy (P= 0.0202, R2= 0.6923; Figure 2C). Although depletion
in the periphery is an indicator of the overall effect of SIV
infection, T cell depletion in the local granuloma environment is
more likely to have an influence on reactivation. It was not
possible to directly sample granulomas to measure T cell
frequencies over the course of SIV infection (except at necropsy,
see below), so we sampled the airways and analyzed BAL cells
instead. The early-reactivating monkeys had lower frequencies of
CD4 T cells (p = 0.0571) in the airway at 10 weeks post-SIV than
monkeys that reactivated later (Figure 2D).
Peripheral IFNc Responses Increase in Response to SIV
Infection
Previous studies using IFNc ELISPOT indicate macaques with
active or reactivating TB have more IFNc-producing PBMCs than
animals with latent TB [21,24]. Given this, we performed IFNc
ELISPOT to determine whether changes in the frequency of Mtb- or
SIV-specific T cells within PBMC could predict reactivation in co-
infected animals (Figure 3). Unexpectedly, numbers ofMtb- and SIV-
specific T cells increased sharply in all monkeys between 7–8 weeks
post SIV infection. This increase in SIV- and Mtb-specific T cells
quickly declined in all late reactivators and one early reactivator. The
number of SIV-specific T cells within the SIV-only group did not
change considerably between 8 and 32 weeks post SIV infection. The
increase in Mtb-specific T cells coincided with an increase in the
Figure 2. Acute CD4 T cell depletion correlates with reactivated TB. A. Mean CD4 and CD8 T cell numbers from whole blood of co-infected
macaques. Upper (CD8) and lower (CD4) error bars have been omitted for clarity. B. Mean CD4 T cell numbers over weeks 1–8 correlate with
reactivation (red line: P = 0.011, R2 = 0.756) and necropsy time (blue line: P = 0.0007, R2 = 0.9172). C. Mean CD8 T cell numbers do not correlate with
reactivation (red line: P = 0.112, R2= 0.426) but do correlate to necropsy time (blue line: P = 0.020, R2 = 0.692). D. Animals that reactivate ,17 weeks
post-SIV infection have a trend toward lower frequencies of CD4 T cell in the BAL at 10 weeks post SIV infection than monkeys .26 weeks post SIV
infection Man-Whitney (P = 0.057). 1207 (early) BAL cells were sampled 8 weeks post SIV infection.
doi:10.1371/journal.pone.0009611.g002
SIV and TB Co-Infection
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expression of late (CD29) but not early (CD69) activation markers on
both CD4 and CD8 T cells (Figure S3). We hypothesized that the
initial burst of Mtb-specific IFNc responses shortly after SIV infection
may reflect a transient perturbation of the local control of infection at
the level of the granuloma, resulting in an increase in antigen load
due to bacterial replication.
Co-Infected Monkeys Had More Pathology, Higher
Bacterial Numbers, and More Dissemination than Latent
Monkeys
Each co-infected monkey displayed clinical indicators of TB
following SIV infection that are not seen in monkeys with latent TB.
Reactivated disease was confirmed at necropsy by pathology- and
microbiology-based measurements that characterize the extent of
visible and microscopic disease. Gross pathology at necropsy was
quantified by a metric referred to as the necropsy score [18] that
reflects the grossly visible tuberculous disease including the number
and size of visible granulomas in each lung lobe and thoracic lymph
node and extent of dissemination beyond the thoracic cavity. The
monkeys that reactivated early post-SIV infection (,17 weeks) had
more TB-related pathology than monkeys that reactivated later post-
SIV infection, and thus had a trend towards higher necropsy scores
(P=0.0571, Figure 4A). We also scored the total bacterial burden for
each monkey, and the percent of tissues sampled at necropsy that
were Mtb culture-positive. A bacterial number score [18] was used to
reflect the total bacterial load and was obtained by summing the log-
transformed number of colony forming units (CFU) from all sampled
tissues. The percent positive score measured the proportion of
sampled tissues that are Mtb culture positive, thereby indicating the
extent of bacterial dissemination in visibly involved and uninvolved
tissues. The co-infected monkeys had gross pathology, percent
positive and bacterial number scores that were similar to SIV-
negative monkeys with active TB and significantly higher than what is
seen in latent monkeys (Figure 4B). These metrics, therefore, support
the pre-necropsy clinical data indicating that the co-infected monkeys
had disease consistent with reactivated TB.
Histology Reveals a Mixture of Chronic and Active
Granulomas in Co-Infected Monkeys
The granulomas seen in active and latent monkeys have been
described previously and are extremely similar to those seen in
human TB [18,21,29]. To summarize, monkeys classified as having
latent infection typically have at least one granuloma in one lung lobe
and associated draining thoracic lymph node(s). These granulomas
are generally caseous with partial or total mineralization, often
combined with extensive peripheral fibrous connective tissue
deposition [18]. Completely fibrotic (sclerotic) lesions are occasionally
observed. In contrast, monkeys with active TB frequently have a
range of lesion types, including caseous with or without peripheral
fibrosis, non-necrotizing (primarily epithelioid macrophages with a
lymphocytic component), and suppurative (with significant neutro-
philic infiltrate) [18]. Mineralized or completely fibrotic lesions
indicative of more chronic immunologic responses to subclinical
(latent) infection are rarely observed in monkeys with active TB.
In general, the co-infected monkeys had a mix of active and
chronic lesions (Table 2). Monkey 1407, which reactivated early
post-SIV infection, had extensive widespread active lesions with
little evidence of chronic disease. Monkeys 2407 and 1207, which
also reactivated early post SIV infection, had pathology consistent
with disseminated active TB (Figure 5A), but additionally showed
some chronic appearing lesions, including a few solid fibrotic
lesions. Certain chronic caseous granulomas had signs of
reactivation foci around the perimeter (Figure 5B) as indicated
by the presence of macrophage and lymphocyte-rich ‘‘satellite’’
granulomas associated with reactivation [18,24]. Monkeys that
reactivated later post-SIV infection experienced a range of
involvement, with 3007 and 1907 having more active-type lesions
than 10405 and 1807, although these monkeys as a group had
fewer active-appearing lesions than the animals that reactivated
earlier following SIV-infection. Additionally, there were more
mineralized granulomas reflecting the original latent infection.
However, a striking finding was the presence of substantially more
completely fibrotic granulomas, especially in 3007, (Figure 5C, 5D
and Table 2) than is normally noted in active or latent monkeys. In
our experience to date, these completely fibrotic granulomas are
usually seen in monkeys that had active disease but were then
treated with anti-tuberculous drugs for 1–2 months (unpublished
data), strongly suggesting that this phenotype represents healing of
active granulomas. These granulomas are occasionally seen in
latent monkeys, but are present in a higher proportion of
granulomas examined histologically from the co-infected monkeys
(Table 2). Table 2 also demonstrates that many more granulomas
were found in the co-infected monkeys than in Mtb-only latent
monkeys, which reflects reactivation and likely the spread of
infection. Taken in the context of the co-infection, a possible
interpretation of the increased presence of completely fibrotic
granulomas is that SIV infection perturbed the local control of the
latent infection, leading to subclinical reactivation in some
monkeys and spread of infection in the lungs, with subsequent
healing of some granulomas as the host controlled virus load and
regained control of the Mtb infection.
Figure 3. Co-infected monkeys experience an increase in numbers of Mtb-specific T cells following early after SIV infection. IFNc
ELISPOTs were performed on PBMCs stimulated with Mtb or SIV antigens. IFN-c was measured in spot forming units (SFU) per 16106 cells.
doi:10.1371/journal.pone.0009611.g003
SIV and TB Co-Infection
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IFNc Production in Tissues Was Not Affected by SIV
Infection
IFNc ELISPOTs were performed on tissue homogenates of
lung lobes at necropsy to determine whether SIV infection
impaired anti-mycobacterial IFNc responses (Figure 6). These
tissues were separated into tissue containing grossly visible
granulomas (involved) and those without (uninvolved). Uninvolved
lung tissue did not demonstrate a strong response to either Mtb or
SIV peptides in any monkeys, except 1907 which had Mtb-culture
positive tissues that did not contain visible granulomas, but likely
had microscopic disease. Two monkeys had very high frequencies
of Mtb and SIV-specific IFNc-producing cells in involved lung
tissue; these monkeys also had the most disease and highest
bacterial burdens. Previously, we demonstrated that IFNc
producing T cells in the tissues of monkeys are higher in monkeys
with more disease, likely reflecting the amount of antigen present
in the tissues, due to higher numbers of bacilli [18]. IFNc
responses to SIV or Mtb antigens in uninfected and infected
thoracic lymph node cells were not significantly different (data not
shown). Co-infected monkeys had similar frequencies of SIV-
specific IFNc-releasing cells compared to SIV-only monkeys (data
not shown).
Correlation between Mycobacterial CFU and Viral Titer
It has been reported that TB-involved lung lobes have higher
virus loads than uninvolved lobes in humans [30], suggesting that
Mtb-related inflammation infection can increase viral replication.
To address this, we directly sampled granulomas and other tissues
at necropsy to measure bacteria and virus loads. While we found a
broad range of Mtb and SIV loads, both between monkeys and
Figure 4. Pathology associated with reactivation in co-infected monkeys. A. Gross pathology at time of necropsy in co-infected monkeys.
Weeks indicates time post-SIV infection for co-infected monkeys or post-Mtb infection for monkey 17706. Necropsy score represents the gross
pathology score, CFU score indicates the bacterial number score. Lungs, thoracic lymph nodes, spleen, liver and kidney are represented. Granulomas
are represented by blue circles, TB pneumonia by orange patches, enlarged thoracic lymph nodes by open ovals, and granulomatous thoracic lymph
nodes by stars. Monkey 17706 is representative of pathology found in latent monkeys. B. Reactivation was quantified by gross pathology score,
bacterial number score and percentage of tissue samples positive for Mtb in homogenized tissue. Co-infected monkeys are statistically different than
latent monkeys (Mann-Whitney, gross pathology P = 0.0025, bacterial number score P = 0.004, % positive samples P= 0.005). Latent monkeys are also
statistically different than active monkeys in gross pathology (Mann-Whitney, P = 0.001, bacterial number score P = 0.0004, and % positive P = 0.0004).
doi:10.1371/journal.pone.0009611.g004
Table 2. Granulomas observed in Mtb-only and SIV-Mtb co-infected monkey.
Total number of
monkeys
Granulomas
examined Caseous Non-necrotic Mineralized
Completely
fibrotic
Active 4 224 62% 36% 1% 1%
Mtb-SIV: early 3 169 39% 57% 3% 1%
Mtb-SIV: Late 4 82 15% 52% 7% 26%
Latent 5 23 4% 0% 82% 13%
doi:10.1371/journal.pone.0009611.t002
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within the same monkey, there was no correlation of viral titers
with bacterial loads in either granulomas or thoracic lymph nodes
(Table S1).
Co-Infected Monkeys Had Fewer T Cells in Involved
Tissues than SIV- or Mtb-Only Animals
To determine that SIVmac251 depleted CD4 T cells in mucosal
(uninvolved) tissue, we compared CD4 and CD8 T cell frequencies
in gut tissue in monkeys with infected with Mtb (no SIV), co-
infected monkeys and an SIV-only monkey. There was substantial
depletion of CD4 T cells in the colon (25.3% Mtb, 5.7% co-
infected) and ileum/jejunum (14.0% Mtb, 1.6% co-infected, 8.6%
SIV only). CD8 T cells were only slightly decreased in the co-
infected monkey gut tissues compared to controls. These data
indicate that SIVmac251 is capable of reducing T cells in the
mucosal tissue, as has been previously reported for rhesus
macaques [31] and for humans (with HIV) [32].
We measured CD4 and CD8 T cell numbers in draining lymph
nodes and TB-involved lung from co-infected monkeys to better
understand how SIV infection affects cell numbers in tissues
infected with TB. A trend of fewer CD4 T cell numbers in the
thoracic lymph nodes of co-infected monkeys compared to SIV-
only monkeys was observed (Figure 7). Viral titers in the draining
lymph nodes of co-infected monkeys and SIV-only monkeys were
not significantly different (data not shown). T cell numbers in lung
tissue were also examined although we did not obtain sufficient
numbers of T cells from lung tissue from SIV-only monkeys for
comparison, probably because these monkeys did not have
pulmonary infections with other pathogens. As previously
reported, T cell numbers are higher in involved lung tissue from
active monkeys compared to latent monkeys [18]. Here, the co-
infected monkeys had T cell numbers similar to the number
observed in latent monkeys (Figure 7) even though they had
significant disease and increased bacterial numbers, similar to
active TB monkeys. This observation suggests co-infected monkeys
may have critical defects in their ability to mount or maintain T
cell-mediated immune responses at the site of infection.
Discussion
Reactivated TB is a major source of morbidity and mortality
among HIV-infected individuals. While most opportunistic
infections commonly occur when CD4 T cell numbers have
significantly declined, TB occurs throughout the entire spectrum
of HIV disease, including when CD4 T cells numbers are well
preserved and stable [4,5,6]. Despite the severe risk of TB in HIV-
infected persons, research into factors underlying early reactiva-
tion has been hampered by lack of appropriate animal models
Figure 5. Histopathology associated with co-infected monkeys. A. Actively disseminating tuberculous disease characterized by
granulomatous inflammation infiltrating into the wall of a large bronchus and adjacent vessel. Hematoxylin and eosin (H&E) stain, 56magnification.
B. A ‘‘satellite’’ nodule (arrow) comprised of non-necrotizing granulomatous inflammation extends from the outer margin of a more chronic caseous
granuloma, suggesting loss of immunological containment and reactivation. Arrowhead indicates mineralized area. H&E stain, 26magnification C. A
chronic granuloma with extensive central fibrous organization in conjunction with a dense circumscribing margin of peripheral fibrosis. H&E stain,
106magnification. D. A solid fibrotic granuloma comprised of maturing fibroblasts depositing a collagenous matrix. H&E stain, 106magnification.
doi:10.1371/journal.pone.0009611.g005
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combining latent TB and HIV infection. In this study, cynomolgus
macaques with latent TB were infected with SIVmac251 to
investigate the factors that could lead to reactivation of latent TB.
All the monkeys with latent TB co-infected with SIV experienced
clinical signs, pathology and bacterial load consistent with
reactivated disease while the Mtb-negative SIV-infected monkeys
did not develop simian AIDS or opportunistic infections within 11
months of infection. SIV-negative cynomolgus macaques with
latent TB have a ,5% chance of undergoing reactivation and can
maintain latent TB without reactivation for more than three years
(unpublished data). These observations suggest that while these
monkeys can control either SIV or latent Mtb infection
independently, SIV-induced immune dysfunction disrupted the
immunologic pressure constraining mycobacterial growth, induc-
ing reactivation. To our knowledge, this is the first animal model
of latent TB where the immunologic and microbiologic responses
to SIV co-infection can be directly investigated.
Although individuals are at a high risk of developing TB within
the first year of HIV-seroconversion [33], clinical studies of HIV-
Mtb co-infection indicate that depletion of peripheral CD4 T cell
numbers is not predictive of when individuals are most likely to
experience TB [6]. However HIV+ individuals with low
peripheral CD4 T cells have been shown to be at greater risk of
developing active TB [34]. All the monkeys experienced T cell
depletion during acute SIV infection, with reactivated TB
occurring during the period when the animals had regained
normal and stable peripheral T cell numbers. Our data suggests
that rather than the T cell numbers during chronic SIV infection
being a major factor in reactivation, the extent of initial depletion
and post-acute recovery may affect ultimate control of latent Mtb
infection. Monkeys 1407 and 2407, which reactivated early post-
SIV, had fewer peripheral T cells than other monkeys and didn’t
recover from the initial depletion as well as monkeys that
reactivated later. Similarly, 1807 and 1907, which also had fewer
peripheral T cells following SIV infection, displayed signs of active
disease earlier than the other late reactivators, supporting the
hypothesis that early perturbations of the immune response may
ultimately affect disease progression. In contrast with this, we also
infected two latent cynomolgus macaques with SHIV89.6 (data
not shown). These monkeys had significant sustained CD4 T cell
depletion in the periphery as has been reported for cynomolgus
macaques infected with SHIV89.6 [27], yet did not experience
reactivation by seven months post-SHIV infection (unpublished
data). Although SHIV89.6 induces a dramatic loss of peripheral
CD4 T cells it did not cause significant decreases of mucosal CD4
T cells (unpublished data). Taken together, these data support the
conventional paradigm that peripheral CD4 T cell populations are
imperfect indicators of an individual’s susceptibility to TB, and
instead indicate that early T cell depletion by SIV (or perhaps
HIV) that depletes both peripheral and mucosal CD4 T cells may
predict risk of reactivation.
Although the link between peripheral cells and maintenance of
latency is not clear, depletion in the periphery shortly after SIV
infection may reflect significant depletion of T cells in the
granuloma. Monkeys 1407 and 2407, which didn’t recover well
from acute SIV infection and reactivated early, displayed more
disease than later reactivators, possibly indicating that significant
disruption occurred within granulomas and the subsequent
inability to replace T cells lead to reactivated TB. This link
between events in the periphery and the local granuloma
environment is supported by the decreases observed in the
frequency of CD4 T cells in the airways from the early-
reactivating macaques. The acute phase of SIV infection was
accompanied by increased numbers of Mtb-specific IFNc-
producing T cells in the periphery. This may be caused by SIV-
induced impairment of granuloma function leading to increased
mycobacterial growth and dissemination, which results in
increased amounts of bacterial antigen released. Taken together,
these data suggest that systemic T cell depletion permits
resumption of bacterial growth and perhaps reactivation. Indeed,
HIV-induced depletion of Mtb-specific CD4 T cells in the
granuloma, and subsequent disruption of cellular architecture
critical [27] for bacterial containment, have been hypothesized as
factors contributing to increased reactivation rates in co-infected
humans [9,35].
The extensive histological examination of granuloma-contain-
ing tissue from animals with widely different amounts of disease
expanded our basic understanding of how HIV may change the
Figure 6. Antigen specific T cells in involved and uninvolved tissue of co-infected monkeys. Tissue homogenates were isolated from the
granulomatous (involved) or tissues without grossly present granulomas (uninvolved) in lung. Monkeys not represented because too few cells were
recovered from tissues at necropsy are indicated by asterisks.
doi:10.1371/journal.pone.0009611.g006
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pathology of tuberculosis. Granulomas from the earliest-reactivat-
ing animals were most similar to animals with active disease [18]
whereas macaques that reactivated later had more mineralized
granulomas, which are most often associated with latent disease,
with evidence for some localized dissemination and reactivation.
The lungs of latent monkeys normally contain few granulomas,
and they are usually either completely calcified lesions or caseous
ones with significant mineralization, with an occasional completely
fibrotic granuloma in some monkeys. The most striking finding in
the co-infected monkeys was the presence of numerous completely
fibrotic granulomas in the lungs, which are rarely seen in latent
infection [18]. We have observed this granuloma type in the
setting of short-term drug treatment in the macaque model
(unpublished data), and thus associate this fibrosis with a healing
response. Our interpretation of this unusual pathology is that the
initial events surrounding SIV infection caused a depression in the
local immune response (the granulomas) in latent animals,
allowing increased bacterial growth, spread to other areas of the
lung, and formation of additional granulomas. After this initial
event, some animals may regain partial control of the infection,
and these new granulomas begin to heal and become fibrotic.
Thus, the interaction of SIV with the latent TB granuloma is a
dynamic, and can lead to various outcomes. The cytokine milieu
in the SIV-infected lungs may also promote more fibrotic-type
healing, leading to the abundance of this type of lesion; this
hypothesis requires further study.
There was a trend of fewer CD4 T cells in the pulmonary
lymph nodes of co-infected monkeys compared to SIV-only
monkeys, indicating that the presence of mycobacteria, and
perhaps the increased T cell activity in the lymph nodes, leads to
more depletion of these cells in the lymphoid tissue, and may
contribute to enhanced disease. Co-infected monkeys had fewer
CD4 and CD8 T cells within TB-involved lung tissues when
compared to SIV-negative monkeys with active TB. This
contradicts what normally happens in animals with active TB,
which have more T cells in involved tissues than latent monkeys.
Significant reductions in T cell numbers within the lung tissue of
the co-infected monkeys suggest that SIV is interfering with
migration of T cells to the site of infection as has been seen with
HIV [36]. Alternatively, SIV may be inducing T cell death within
the granuloma like that observed in HIV-Mtb co-infected humans
[37]. Exposure to Mtb antigens is linked to apoptosis in HIV-
Figure 7. CD4 and CD8 T cell numbers in lung and thoracic lymph nodes. CD4 and CD8 T cell numbers in lung-draining thoracic lymph
nodes (LN) are not significantly different between co-infected animals and animals with latent or active TB. T cell numbers in co-infected lung tissues
were similar to animals with latent TB but significantly lower than animals with active TB (Mann-Whitney, CD4 P= 0.0023; CD8 P=0.0078). Latent
monkeys have fewer lung T cells than active monkeys (Mann-Whitney, CD4 P=0.0014; CD8 P= 0.0018). Data points represent average T cell numbers
from either thoracic LN or lung tissue from each monkey. Not all co-infected monkeys are not present due to limited tissue availability.
doi:10.1371/journal.pone.0009611.g007
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infected cells [38], which could mechanistically explain why tissues
in co-infected animals were depleted when compared with animals
only infected with Mtb. To our knowledge, this study provides the
first evidence demonstrating quantitative T cell depletion within
granulomatous tissue, supporting hypotheses for mechanisms by
which HIV disrupts the maintenance of latent Mtb infection [8,9].
Several groups have investigated the effects of HIV-Mtb co-
infection on the replication of both pathogens [39,40,41,42] and the
relationship between virus load and disease progression [7,43,44].
We found similar peripheral and tissue virus loads in co-infected and
SIV-only monkeys, suggesting that virus loads were not influenced
by Mtb infection. Granulomatous tissue might be an ideal
environment for HIV replication as abundant T cells, increased
cell-cell interaction, and high TNF expression promote cell-cell
transmission and virus replication [9,40,42]. We were unable to
confirm this, however, and could not correlate virus loads with Mtb
burden in individual granulomas (Table S1). Differences in viral titer
did not appear to be the cause of reactivation either, as viral titers
(peak and during the chronic phase) were similar between the early
and late reactivators. Similar findings have come from the HIV-TB
clinical literature [45,46], highlighting the clinical relevance of the
cynomolgus macaque co-infection model. Our viral titers were
relatively low following the acute infection, however, and it is
possible that higher viral titers in a different macaque species or with
a different virus strain could lead to different results. Even with the
low virus loads observed in these cynomolgus macaques they all
experienced reactivation of latent TB.
We have developed a tractable animal model of reactivated TB
in HIV-co-infected humans. Although numerous clinical studies
have been undertaken to investigate HIV-Mtb co-infection, most
examine patients with active TB and many are either retrospective
or limited by the number and types of tissues and time points that
could be sampled. This novel model will be a useful tool for
investigating interactions between Mtb and HIV, and the
immunologic events that lead to reactivation of latent TB or
exacerbation of primary infection.
Supporting Information
Figure S1 Schematic representation of experimental design.
Two groups of animals were established, a SIV-only control group
and a Mtb-SIV co-infection group. Historical controls based on
other studies were used as Mtb-only controls for active or latent
TB. Green indicates the time where Mtb-only, pre-SIV infection
baseline data were acquired. Red indicates 0–8 weeks post-SIV
infection where blood was drawn weekly, BAL cells and gastric
aspirates were acquired every four weeks and lymph node biopsies
were done at four and eight weeks post-SIV. Light blue (SIV-only)
indicates where monthly blood draws and BAL procedures were
performed. Dark blue (Mtb-SIV co-infected) indicates where
blood draws for ELISPOT assays and virus load determination
were performed every other week, BAL cells and gastric aspirates
were acquired every four weeks and lymph node biopsies were
performed at weeks 12 and 24 post-SIV infection. No SIV-only
animals experienced any sAIDS-like symptoms.
Found at: doi:10.1371/journal.pone.0009611.s001 (0.38 MB TIF)
Figure S2 Changes in T cell frequencies in the peripheral lymph
nodes of co-infected macaques. Peripheral (inguinal or axillary)
lymph node biopsies were performed on co-infected monkeys at 0,
4, 12, and 24 weeks post SIV inoculation. Numbers represent early
(1207, 1407, 2407) and late (1807, 1907, 3007, 10405) reactivator.
Found at: doi:10.1371/journal.pone.0009611.s002 (5.40 MB TIF)
Figure S3 T cell activation markers increase following SIV
infection. Changes in the expression of early (CD69) and late
(CD29) activation markers are represented in CD4 or CD8
peripheral T cells over time.
Found at: doi:10.1371/journal.pone.0009611.s003 (8.63 MB TIF)
Table S1 Virus and bacterial burden in uninvolved and involved
tissues.
Found at: doi:10.1371/journal.pone.0009611.s004 (0.05 MB
DOC)
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